PRS 101 FOUNDATIONS OF PHARMACY REGULATION PRS 101.3: THE DRUG ENFORCEMENT ADMINISTRATION REGULATORY ROLE DR. BRUSHWOOD S MONOGRAPH



Similar documents
OVERVIEW OF RECENT PHARMACY LAW CASES DAVID BRUSHWOOD, JD, RPH

PRS 103 CONTEMPORARY ISSUES IN PHARMACY REGULATION PRS 103.6: LICENSURE AS ASSURANCE OF COMPETENCE DR. BRUSHWOOD S MONOGRAPH

PRS 105 REGULATORY COMPLIANCE CASE STUDIES PRS 105.7: THE WHISTLEBLOWER DR. BRUSHWOOD S MONOGRAPH

NATURAL MEDICINES TO MANAGE DIABETES

A REVIEW OF FEDERAL PHARMACY LAW DONALD SULLIVAN, PH.D

PREVENTING MEDICATION ERRORS IN PHARMACY PRACTICE DR. SULLIVAN S SUPPLEMENTAL HANDOUT

OH MY ACHING BODY: TACKLING FIBROMYALGIA GENEVA BRIGGS, PHARMD, BCPS

BE WISE, IMMUNIZE: AN UPDATE ON IMMUNIZATION PRACTICES GRETCHEN KRECKEL GAROFOLI, PHARMD

DEFENDING A FEDERAL CRIMINAL CHARGE AND A BOARD ACTION ROBERT ESGRO, RPH, ESQ

NEW AND EMERGING THERAPIES IN THE TREATMENT OF SEASONAL ALLERGIES

REVIEW OF FEDERAL LAW FOR PHARMACY TECHNICIANS DR. SULLIVAN S MONOGRAPH

WHEN THE STARS ALIGN AND YOUR PATIENT IS IN SYNC: ADHERENCE RISES MARK GAROFOLI, PHARMD, MBA, CGP PETE KRECKEL, RPH

RHEUMATOID ARTHRITIS: PRIMARILY AN AUTOIMMUNE DISEASE JOHNATHON DUFTON, MD

MOVEMENT BEYOND LAXATIVES: EVOLVING PHARMACOLOGIC OPTIONS FOR IBS-C AND CIC PETE KRECKEL, RPH

ON PENS AND NEEDLES A PRIMER ON INSULIN PENS AND PROPER INJECTION TECHNIQUES PETE KRECKEL, RPH

NEW UPDATES IN OTC PRODUCTS: 2014 DONALD SULLIVAN, PHARMD

CAN SUPPLEMENTS BE USED TO MANAGE ATTENTION DEFICIT/HYPERACTIVITY DISORDER? GENEVA BRIGGS, PHARMD, BCPS

TESTOSTERONE REPLACEMENT THERAPY FOR THE AGING MALE: COUNSELING INSIGHTS FOR THE PHARMACIST TIM DRAKE, PHARM.D.

SHOULD WE ALL TAKE OMEGA-3 FATTY ACID SUPPLEMENTS? GENEVA BRIGGS, PHARMD, BCPS

ALL IN THE FAMILY 75 YEARS OF DIABETES TREATMENT OPTIONS FROM GLASS SYRINGES TO SGLT2 INHIBITORS PETER A. KRECKEL, R.PH.

ANTIBIOTICS FROM HEAD TO TOE: PART 5 - URINARY TRACT INFECTIONS LAUREN HYNICKA, PHARM.D.

MEMBER S CHOICE: THE REQUESTED SPANISH PHRASES FOR THE PHARMACY STEPHANIE LANGSTON, MFLE

UNDERSTANDING AND TREATING ADHD TAMMIE LEE DEMLER, PHARMD, MBA, BCPP

A FOCUS ON TOPICS IN OHIO PHARMACY LAW -- OHIO STATE BOARD OF PHARMACY APPROVED DR. SULLIVAN S MONOGRAPH

How To Get A Prescription In Rhode Island

MEETING OF THE DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEETING: RISKS AND BENEFITS OF HYDROCODONE COMBINATION ANALGESIC PRODUCTS

Exceptions to the Rule: A Pharmacy Law Presentation. Objectives DISCLAIMER 10/16/2015

Privacy Space. Public Place. How to Protect PHI and be HIPAA Compliant

Substance Use: Addressing Addiction and Emerging Issues

PHARMACY TECHNICIAN LICENSURE S.B. 92: ANALYSIS AS ENACTED

What Every Practitioner Needs to Know About Controlled Substance Prescribing

ANALYSIS AS REPORTED FROM COMMITTEE

Opioid Prescribing Practices and Pain Management: Role of FDA Douglas C. Throckmorton, MD Deputy Director for Regulator Programs, CDER, FDA

2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC

Massachusetts Substance Abuse Policy and Practices. Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District

Office-Based Treatment of Opioid Dependence

Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998

Colorado Prescription Drug Monitoring Program. Department of Regulatory Agencies Division of Professions and Occupations State Board of Pharmacy

Overview of Recent Pharmacy Law Cases

For a Healthier America: Reducing Prescription Drug Misuse and Abuse

State Advocacy Guide to Prescription Drug Monitoring Program Legislation and Regulations

247 CMR: BOARD OF REGISTRATION IN PHARMACY

"Electronic Prescribing of Controlled Substances: Addressing Health Care and Law Enforcement Priorities" Before the Senate Judiciary Committee

STATE PLAN TO PREVENT AND TREAT PRESCRIPTION DRUG ABUSE RECOMMENDATION SUMMARY Governor s Prescription Drug Abuse Prevention Council

Treating Pain: New Guidelines for Using Controlled Substances. Jason F. Arnold, JD, MPH Associate Director, Institute of Human Values in Health Care

Information for Pharmacists

2015 REPORT Steven W. Schierholt, Esq. Executive Director

CHAPTER 10 PHARMACY TECHNICIAN REGULATIONS. These regulations are promulgated as authorized by the Act.

DEA Washington Division Diversion Control Program

CURES Prescription Drug Monitoring Program

Increasing Access to Opioid Addiction Treatment

PRESCRIPTION MONITORING PROGRAM STATE PROFILES LOUISIANA

U.S. Bureau of Labor Statistics. Pharmacy Tech

CHAPTER 10 PHARMACY TECHNICIAN REGULATIONS. These regulations are promulgated as authorized by the Act.

Prescription drug abuse trends. Minnesota s Prescription Monitoring Program. Minnesota Rural Health Conference June 25, 2013 Duluth

2015 Annual Convention

Prescription Drug Monitoring Program Administrators Guide for Training Law Enforcement

How To Become A Pharmacy Technician

REGULATION 3 PHARMACY TECHNICIANS

What you should know about treating your pain with opioids. Important information on the safe use of opioid pain medicine.

HOUSE OF REPRESENTATIVES STAFF ANALYSIS REFERENCE ACTION ANALYST STAFF DIRECTOR

5 year analysis of Pharmacy Burglary and Robbery Experience

CHAPTER 10 PHARMACY TECHNICIAN REGULATIONS TABLE OF CONTENTS

Prescription Drug Monitoring Program. A Powerful Tool

MA Healthcare Reform Legislation: Assessment of Massachusetts Department of Public Health Regulations

How To Treat Anorexic Addiction With Medication Assisted Treatment

NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS

Pharmacy Jurisprudence, LLC

Michigan Board of Nursing Guidelines for the Use of Controlled Substances for the Treatment of Pain

Pharmacy Technology Program Student Handbook

The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section

MEDICAL ASSISTANCE BULLETIN

Delaware. Division of Professional Regulation, Office of Controlled Substances Professional Licensing Agency

SCOPE of Pain: Safe and Competent Opioid Prescribing Education

CHAPTER 10 PHARMACY TECHNICIAN REGULATIONS. These regulations are promulgated as authorized by the Act.

Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain

2014 Legislative Session. Disclosure. Florida Pharmacy Laws(Statutes) Objectives (1) Pharmacy Technician. FL Pharmacy Law Update May 24, 2014

WHAT WE KNOW. Collective Action Issue Brief #2 Updated June 2014 PRESCRIPTION PAIN MEDICATION MISUSE

Purpose What s new? Role of pharmacists and pharmacy technicians in physician-assisted death... 3

Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015

Treatment Programs (OMTP)

02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION

Controlled substances Identifying risks and internal audit focus areas

PROPOSED ADMINISTRATIVE REGULATION. Joint Academic Senate Student Affairs Committee

Pharmacy Law Overview. From Civil Liability to Criminal Prosecution

11/26/2012. Implementation of Florida s PDMP. Disclosure

MEDICAL ASSISTANCE BULLETIN

Pharmacy Program Pre-Test

The New Pharmacology for Medical Careers

SENATE... No The Commonwealth of Massachusetts. In the Year Two Thousand Fourteen

Federal Regulations For Prescribing Scheduled Controlled Substances

Published by Waterford Life Sciences, Washington, DC Cover and book design: Gretchen Maxwell, GLM Design

The Prescription Drug Abuse and Heroin Crisis: New York s Response

INFORMATION BRIEF. Overview. Prescription Drug Abuse Among Young People

Controlled Substances Prescription Monitoring Program. Dean Wright, RPh Arizona State Board of Pharmacy

PRESCRIPTION PAINKILLER OVERDOSES

DISTRICT OF COLUMBIA MUNICIPAL REGULATIONS FOR PHARMACY TECHNICIANS

PA CME Requirements. Alaska Alaska Physician Assistants must maintain an active NCCPA certification for license renewal.

Federal & State Laws Related to Prescribing Controlled Substances

DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR S OFFICE PHARMACY TECHNICIANS. Filed with the Secretary of State on

Transcription:

PRS 101 FOUNDATIONS OF PHARMACY REGULATION PRS 101.3: THE DRUG ENFORCEMENT ADMINISTRATION REGULATORY ROLE DR. BRUSHWOOD S MONOGRAPH

PRS 101.3 THE DRUG ENFORCEMENT ADMINISTRATION REGULATORY ROLE ACTIVITY DESCRIPTION This class explores how a law enforcement agency with a traditional supply-side focus on the interdiction and elimination of illicit drugs with no medical value, can expand its role into reducing abuse of prescription drugs that do have a legitimate role in medicine. The success of the War on Drugs is considered, along with the consequences of the warfare strategy toward drug abuse. The class compares the regulatory approaches of voluntary compliance and strong enforcement. The class reviews the regulatory implications for pharmacists of state assisted suicide and medical marijuana laws. This monograph can be taken as a standalone 1 credit hour home study in law (ACPE accredited) but is also a component of the Pharmacy Regulatory Specialist curriculum. To qualify as a PRS, one must enroll in each of the five (5) live PRS pharmacy law webinars given throughout the year and successfully complete twenty-six (26) one-credit monographs. Once all requirements have been completed, the participant must pass a final comprehensive exam (70% or higher) and pay $199 for the recording and issuing of the Pharmacy Regulatory Specialist Certificate. TARGET AUDIENCE The target audience for this activity is pharmacists and pharmacy technicians in hospital, community, and retail pharmacy settings. LEARNING OBJECTIVES After completing this activity, the pharmacist will be able to: Describe the authority of the DEA under the CSA Discuss the crisis of prescription drug abuse List major requirements for pharmacies under DEA regulations. ACCREDITATION PHARMACY PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. NURSING PharmCon, Inc. is approved by the California Board of Registered Nursing (Provider Number CEP 13649) and the Florida Board of Nursing (Provider Number 50-3515). Activities approved by the CA BRN and the FL BN are accepted by most State Boards of Nursing. CE hours provided by PharmCon, Inc. meet the ANCC criteria for formally approved continuing education hours. The ACPE is listed by the AANP as an acceptable, accredited continuing education organization for applicants seeking renewal through continuing education credit. For additional information, please visit http://www.nursecredentialing.org/renewalrequirements.aspx Universal Activity No.: 0798-0000-14-032-H03-P&T Credits: 1 contact hour (0.1 CEU) Release Date: April 1, 2014 Expiration Date: April 1, 2016 ACTIVITY TYPE Knowledge-Based Home Study Monograph FINANCIAL SUPPORT BY PharmCon After completing this activity, the pharmacy technician will be able to: Describe the authority of the DEA under the CSA Discuss the crisis of prescription drug abuse List major requirements for pharmacies under DEA regulations 1

ABOUT THE AUTHOR David Brushwood is professor of Pharmaceutical Outcomes and Policy at the University of Florida College of Pharmacy. A graduate of the schools of pharmacy and law at the University of Kansas, professor Brushwood practiced both professions prior to entering academia. Professor Brushwood has developed error prevention programs for several pharmacy chains. His research interests are in the areas of regulating for outcomes, medication error prevention, and pain management policy. He has received grant funding from numerous agencies including the Robert Wood Johnson Foundation, the National Institutes of Health, and the National Community Pharmacy Foundation. Professor Brushwood received the 2012 Pellegrino Medal. The award honors nationally-recognized leaders for contributions to healthcare ethics in the selfless spirit of Edmund D. Pellegrino. He also has twice been selected as a Mayday Scholar in Pain Policy by the American Society of Law, Medicine & Ethics. Professor Brushwood is a frequent contributor to pharmacy journals and to law journals. He developed, and serves as an advisor for the UF online Master of Science in Pharmacy, a graduate program offering seven areas of specialization in regulatory pharmaceutical fields. David Brushwood, JD, RPh Professor, University of Florida School of Pharmacy FACULTY DISCLOSURE It is the policy of PharmCon, Inc. to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer of any commercial product(s) and/or service(s) discussed in an educational activity. David Brushwood reports no actual or potential conflict of interest in relation to this activity. Peer review of the material in this CE activity was conducted to assess and resolve potential conflict of interest. Reviewers unanimously found that the activity is fair balanced and lacks commercial bias. Please Note: PharmCon, Inc. does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced and objective. Occasionally, authors may express opinions that represent their own viewpoint. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient or pharmacy management. Conclusions drawn by participants should be derived from objective analysis of scientific data presented from this monograph and other unrelated sources. 2

3

4

5

6

7

8

9

10

ACTIVITY TEST 1. In what year did US Congress pass the Harrison Narcotics Tax Act? A. 1906. B. 1914. C. 1970. D. 1973. 2. According to the Federation of State Medical Boards (FSMB), there is a state of biologic adaptation evidenced by a withdrawal syndrome when the drug is abruptly discontinued. What is this called according to FSMB definitions? A. Abuse. B. Tolerance. C. Dependence. D. Addiction. 3. According to the Supreme Court of the United States, what is the status of state-approved medical marijuana under federal law? A. Legal, because states have the right to determine what constitutes appropriate medical use. B. Legal, because the DEA approves of medical marijuana. C. Illegal, because consuming one s locally grown marijuana affects interstate commerce in marijuana. D. Illegal, because users of marijuana are hardened criminals who threaten society. 4. According to the Supreme Court of the United States, what is the status of state-approved assisted death under federal law? A. Legal, because states have the right to determine what constitutes appropriate medical use. B. Legal, because the CSA specifically approves assisted death as a legitimate medical purpose. C. Illegal, because assisted death in one state affects the dying process in all states. D. Illegal, because assisting death is immoral and it threatens society. 5. In what year was OxyContin approved? A. 1996. B. 1998. C. 2000. D. 2002. 11

6. What is the best solution to the problem of prescription drug abuse? A. Abuse-deterrent technology that uses an opioid antagonist. B. Abuse-deterrent technology that creates a gummy matrix when a tablet is crushed. C. Abuse-deterrent technology that includes a low dose of an aversive drug. D. A new molecule that is not abused. 7. If a wholesaler discovers a suspicious order from a pharmacy, to whom must this suspicious order be reported? A. The pharmacy s pharmacist in charge. B. The local police. C. The state board of pharmacy. D. The DEA. 8. With what frequency must a pharmacy DEA registration be renewed? A. Every year. B. Every two years. C. Every three years. D. Every four years. 9. If a pharmacy experiences a theft or significant loss of controlled substances, on what form must this be reported to the DEA? A. Form 41. B. Form 106. C. Form 222. D. Form 222a. 10. In a LTCF that has an automated dispensing system (ADS), drugs still contained within the system are considered whose property? A. They are considered LTCF property. B. They are considered pharmacy stock. C. They are considered the patient s property. D. They are considered the prescriber s property. Please submit your final responses on freece.com. Thank you. 12